RxDoctor Payments Data

Beth Diner, MD

Obstetrics & Gynecology · St Petersburg, FLNPI 1790765857

Payments from drug & device makers

$1,053in general payments, 2019–2025

Across 46 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$284
  • Millicent US Inc$94
  • Exeltis, USA Inc.$90
  • Bayer$66
  • Sumitomo Pharma America, Inc.$57
  • Organon$55
  • plus $407 from 15 others

What the payments were for

  • Food & beverage$90386%
  • Education$15014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc10$284
Millicent US Inc5$94
Exeltis, USA Inc.4$90
Bayer3$66
Sumitomo Pharma America, Inc.3$57
Organon3$55
Convatec Inc.2$48
Monaghan Medical Corporation1$45
AbbVie2$42
Integra Lifesciences Corporation1$39
Mayne Pharma Commercial LLC1$36
Northgate Technologies, Inc.1$33
AMAG Pharmaceuticals, Inc.2$26
Optumhealth Care Solutions, LLC1$23
Organogenesis Inc.1$21
American Regent1$19
Meditrina1$18
Coopersurgical, Inc.1$16
Smith+Nephew1$15
Pfizer1$13
Dysis Medical, Inc.1$13

How this compares

$1,053 in reported general payments places this provider in the 50th percentile of 2,438 obstetrics & gynecology providers in Florida.

See all obstetrics & gynecology providers in Florida

Medicare billing

Part B allowed, 2024
$46,820
Medicare patients
238
Services billed
567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol200$15,553
PremarinEstrogens, Conjugated41$14,029
MyrbetriqMirabegron15$10,370
Estradiol (Twice Weekly)Estradiol92$6,327
ProgesteroneProgesterone, Micronized148$5,369
YuvafemEstradiol11$1,420
ValacyclovirValacyclovir Hcl42$1,261
Estradiol (Once Weekly)Estradiol17$814
Acyclovir11$191
Clobetasol EmollientClobetasol Propionate/Emoll11$188
Fluconazole25$109
Clobetasol Propionate14$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$13$14,02941 claims
Astellas Pharma US IncMyrbetriq$284$10,37015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,438 obstetrics & gynecology providers in Florida.

Other obstetrics & gynecology in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →